<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37814886</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8301</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Future oncology (London, England)</Title><ISOAbbreviation>Future Oncol</ISOAbbreviation></Journal><ArticleTitle>Real-world treatment patterns, healthcare resource utilization&#xa0;and costs among patients with peripheral T-cell lymphoma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2217/fon-2023-0615</ELocationID><Abstract><AbstractText><b>Objective:</b> To evaluate treatment patterns, healthcare resource utilization (HRU)&#xa0;and costs among peripheral T-cell lymphoma (PTCL) patients in the USA. <b>Methods:</b> A retrospective cohort study, using the&#xa0;IQVIA PharMetrics<sup>&#xae;</sup> Plus claims database from 1&#xa0;April 2011 to 30&#xa0;November 2021, identified PTCL patients receiving systemic treatments. Three mutually exclusive subcohorts were created based on line of therapy (LOT): 1LOT, 2LOT&#xa0;and &#x2265;3LOT. Common treatment regimens, median time on treatment, all-cause and PTCL-related HRU and costs were estimated. <b>Results:</b> Among 189 PTCL patients identified, 61.9% had 1LOT, 21.7% had 2LOT&#xa0;and 16.4% had &#x2265;3LOT. The most common treatment regimens in the 1LOT were CHOP/CHOP-like, CHOEP/CHOEP-like&#xa0;and brentuximab vedotin; monotherapies were most common in the 2LOT and &#x2265;3LOT. All-cause and PTCL-related hospitalizations and prescriptions PPPM increased with increasing LOT. Nearly 70% of total treatment costs were PTCL related. <b>Conclusion:</b> Higher utilization of combination therapies in the 1LOT and monotherapies in subsequent LOTs were observed, alongside high PTCL-related costs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dharmani</LastName><ForeName>Charles</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3641-9738</Identifier><AffiliationInfo><Affiliation>Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ 07920, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unni</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0667-6277</Identifier><AffiliationInfo><Affiliation>Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ 07920, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Ngan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0006-5979-1224</Identifier><AffiliationInfo><Affiliation>IQVIA, 2400 Ellis Road, Durham, NC 27703, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaikh</LastName><ForeName>Nazneen Fatima</ForeName><Initials>NF</Initials><Identifier Source="ORCID">0000-0002-4184-1610</Identifier><AffiliationInfo><Affiliation>IQVIA, 2400 Ellis Road, Durham, NC 27703, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-1212-5516</Identifier><AffiliationInfo><Affiliation>Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ 07920, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vashi</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0003-4653-5377</Identifier><AffiliationInfo><Affiliation>Rutgers University, 160 Frelinghuysen Rd, Piscataway, NJ 08854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fofah</LastName><ForeName>Oluwatosin</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2470-8276</Identifier><AffiliationInfo><Affiliation>Rutgers University, 160 Frelinghuysen Rd, Piscataway, NJ 08854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strubing</LastName><ForeName>Alessandria</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0007-1894-3372</Identifier><AffiliationInfo><Affiliation>Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ 07920, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salas</LastName><ForeName>Maribel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5634-1558</Identifier><AffiliationInfo><Affiliation>Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ 07920, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Nora</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9034-199X</Identifier><AffiliationInfo><Affiliation>Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ 07920, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wooddell</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ 07920, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>IQVIA, 2400 Ellis Road, Durham, NC 27703, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Near</LastName><ForeName>Aimee</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9423-8244</Identifier><AffiliationInfo><Affiliation>IQVIA, 2400 Ellis Road, Durham, NC 27703, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Future Oncol</MedlineTA><NlmUniqueID>101256629</NlmUniqueID><ISSNLinking>1479-6694</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Peripheral T-cell lymphomas (PTCL) are a rare and fast-growing form of blood cancer. About 8000&#x2013;12,000 people in the USA are diagnosed with PTCL every year. As it is a rare disease and has many types, and there is a limited understanding of the patients who have PTCL&#xa0;and the treatments they receive in the real world. The purpose of this study was to evaluate how these patients are treated, what are they treated with&#xa0;and what are the costs of these treatments in the USA. The data collected on these patients was divided into three groups based upon the number of lines of treatment/therapy (LOT) they received: 1LOT, 2LOT&#xa0;and &#x2265;3LOT. This study researched different treatments and their duration in each line of therapy. Among 189 PTCL patients included in the study, the average age of patients was 55&#xa0;years and 62% were male. Among these patients, 62% had 1LOT, 22% had 2LOT&#xa0;and 16% had &#x2265;3LOT. The most common treatments in the 1LOT were traditional chemotherapy regimens followed by targeted therapies: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOP-like, CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone) or CHOEP-like, and brentuximab vedotin. Treatment regimens with only one drug were most common in the 2LOT and &#x2265;3LOT. The total cost of PTCL treatment in the USA is very high; 70% of this cost is related to their treatment with various drugs. More research is needed to better understand the treatment and cost of this rare cancer.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHOEP</Keyword><Keyword MajorTopicYN="N">CHOP</Keyword><Keyword MajorTopicYN="N">brentuximab</Keyword><Keyword MajorTopicYN="N">healthcare costs</Keyword><Keyword MajorTopicYN="N">healthcare resource utilization</Keyword><Keyword MajorTopicYN="N">lines of therapies</Keyword><Keyword MajorTopicYN="N">non-Hodgkin's lymphoma</Keyword><Keyword MajorTopicYN="N">peripheral T-cell lymphoma</Keyword><Keyword MajorTopicYN="N">real-world study</Keyword><Keyword MajorTopicYN="N">treatment patterns</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37814886</ArticleId><ArticleId IdType="doi">10.2217/fon-2023-0615</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>